[324 Pages Report] The paediatric spasticity treatment market is expected to register a CAGR of 10% during the forecast period.
The global paediatric spasticity treatment market is fueled by rising demand for combination products such as benzodiazepines, imidazole, and gamma-aminobutyric acid analogs. In addition to this, demand for paediatric spasticity treatment is rising on account of raising awareness and investing in research and development.
| Attributes | Details |
|---|---|
| Paediatric Spasticity Treatment Market CAGR | 10% |
| Paediatric Spasticity Treatment Market Size | US$ 1.11 Billion in 2022 |
Improvement in healthcare infrastructure is also projected to contribute to the growth of the paediatric spasticity treatment market share.
The report sheds light on the factors improving the sales of paediatric spasticity treatment and, in turn, the opportunities for the market players. However, the paediatric spasticity treatment market also faces some challenges, which might limit the paediatric spasticity treatment market share from reaching its potential.
Some of the key paediatric spasticity treatment market trends promoting the demand for paediatric spasticity treatment include improvements in the innovation and technology in the industry as well as growing awareness of the pediatric spasticity treatment.
The advancement and development of new therapeutic treatments, as well as the growing number of clinical trials for paediatric spasticity treatment, provide a significant opportunity for the sales of paediatric spasticity treatment to grow over the forecast period.
In order to design a scale plan, organizations engaged in the paediatric spasticity treatment market must first identify their future goals, then analyze the many types of scale that could help them reach those goals, and finally decide which type of scale will bring the greatest organizational value.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing awareness, growing research and development for drug development drive the sales of paediatric spasticity treatment in the near future. Changing lifestyle, developing new and innovative technology, and improving healthcare infrastructure are expected to fuel the demand for paediatric spasticity treatment in the forecast period.
The launch of novel therapeutics and growing per capita income in emerging economies such as China and Brazil is further driving the sales of paediatric spasticity treatment.
Some key factors that might hinder the growth of paediatric spasticity treatment market include the high cost of treatment and low awareness in underdeveloped and developing countries, and rigorous regulations for the approval of drug.
The progress and development of new therapeutic treatments, as well as the growing number of clinical trials for paediatric spasticity treatment, provide a significant opportunity for the demand for paediatric spasticity treatment to grow over the forecast period. Collaboration and partnership among leading companies for the development of novel medications, as well as increased research funding, will boost the sales of paediatric spasticity treatment in the near future.
North America is expected to contribute to a major share in the global paediatric spasticity treatment market, owing to the increasing population, increasing number of screening procedures, presence of major manufacturers, and growing clinical trials.
Well-developed healthcare facilities and government funding for drug development further drive the sales of paediatric spasticity treatment. Europe contributes the second-largest share with significant growth in the demand for paediatric spasticity treatment owing to technological advancement in the treatment coupled with growing adoption of a new treatments. Asia Pacific paediatric spasticity treatment market is primarily driven by the factors such as growing prevalence, increasing population, and growing awareness of new treatment options.
China is expected to register rapid growth in the sales of paediatric spasticity treatment due to the large patient pool and availability of new drugs for the paediatric spasticity treatment. Latin America and Middle East & Africa are projected to show a slow rise in demand for paediatric spasticity treatment due to less awareness, lack of adequate healthcare facilities, and less developed infrastructure.
Principal Consultant
Some of the key players present in the global paediatric spasticity treatment are Allergan plc, Ipsen Biopharmaceuticals, Inc., Almirall, S.A, Piramal Critical Care, Inc., Genentech, Inc, Sanofi, Saol Therapeutics, and US WorldMeds, LLC among others.
The demand for paediatric spasticity treatment is moderately competitive, with several significant players. In terms of sales of paediatric spasticity treatment, just a few of the market's top firms are currently producing new products to solve unmet market challenges.
Recent Developments in the paediatric spasticity treatment market include:
The US Food and Drug Administration (FDA) accepted a supplementary Biologics License Application for XEOMIN in August 2020. (incobotulinumtoxinA).
The United States Food and Drug Administration (FDA) approved the expanded use of Dysport (abobotulinumtoxinA) for the treatment of Spasticity in paediatric patients in July 2020, according to Ipsen Biopharmaceuticals.
The report consists of key players, contributing to the paediatric spasticity treatment market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analysis the competitive landscape and paediatric spasticity treatment market share acquired by players to strengthen their market position.
| Report Attribute | Details |
|---|---|
| Growth rate | CAGR of 10% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2021 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Drug type, route of administration, distribution channel, region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Allergan plc; Ipsen Biopharmaceuticals Inc.; Almirall; S.A; Piramal Critical Care, Inc.; Genentech Inc; Sanofi; Saol Therapeutics; US WorldMeds, LLC among others. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The paediatric spasticity treatment market is likely to register a CAGR of 10% during the forecast period.
Key players holding substantial paediatric spasticity treatment market share include Allergan plc, Ipsen Biopharmaceuticals, Inc., Almirall, S.A, Piramal Critical Care, Inc., Genentech, Inc, Sanofi, Saol Therapeutics, and U.S. WorldMeds, LLC among others.
Demand for paediatric spasticity treatment is likely to rise on the back of increasing global awareness and consistent investment in research and development.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032 5.3.1. Baclofen or Muscle Relaxants 5.3.2. Botox 5.3.3. Intrathecal Baclofen 5.3.4. Clonazepam 5.3.5. Diazepam 5.3.6. Tizanidine 5.3.7. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032 6. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 7. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032 7.3.1. Hospitals Pharmacies 7.3.2. Drug Stores 7.3.3. Retail Pharmacies 7.3.4. Mail Order Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032 8. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Russia 11.2.1.6. BENELUX 11.2.1.7. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Rest of Asia Pacific 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Turkey 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Paediatric Spasticity Treatment Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Drug Type 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Drug Type 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Drug Type 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Drug Type 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Drug Type 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. Italy 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Drug Type 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Drug Type 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. U.K. 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Drug Type 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Russia 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Drug Type 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. BENELUX 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Drug Type 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Drug Type 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Drug Type 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Drug Type 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. GCC Countries 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Drug Type 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. South Africa 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Drug Type 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Turkey 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Drug Type 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Allergan plc 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Ipsen Biopharmaceuticals 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Almirall 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Piramal Critical Care 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Genentech 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Sanofi 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Saol Therapeutics 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. US WorldMeds 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Healthcare
September 2024
REP-GB-2345
Upcoming
Explore Healthcare Insights
View Reports
Paediatric Spasticity Treatment Market
